Bristol-Myers Squibb (BMS) is a major producer of therapies for cardiovascular, metabolic and infectious diseases, central nervous system and dermatological disorders, and cancer. The medicines business consists of worldwide pharmaceuticals and consumer medicines.
While BMS experienced the negative impact of generic competition in its pharmaceutical business, it says that it was successful in launching several new products, expanding key businesses and advancing its pipeline. As a result, BMS says that it is now well positioned to begin growing sales and earnings, and to build shareholder value.
The company will continue to execute its strategy for long term growth by increasing investments behind growth drivers and focusing the company's research and development programmes on products that address significant unmet medical needs.
Download the The ICIS Top 100 Chemical Companies listing here